Beam Therapeutics
Beam Therapeutics Logo
About Beam Therapeutics
Beam Therapeutics Inc. is a biotechnology company focused on developing precision genetic medicines using DNA base editing technologies. The company is advancing a pipeline of investigational therapies, including BEAM-101 for sickle cell disease, BEAM-302 for severe alpha-1 antitrypsin deficiency, and BEAM-301 for glycogen storage disease 1a. Beam is also developing BEAM-103, an anti-CD117 monoclonal antibody, BEAM-104, a cell therapy for sickle cell disease and beta-thalassemia, and BEAM-201 and other ex vivo CAR-T therapies. The company collaborates with partners such as Pfizer, Apellis Pharmaceuticals, Verve Therapeutics, Sana Biotechnology, and Orbital Therapeutics to advance base editing and gene therapy programs targeting rare genetic diseases and other serious conditions. Founded in 2017, Beam Therapeutics is headquartered in Cambridge, Massachusetts.
Address
238 Main Street,
Cambridge, 02142
United States
Year founded
2017
Number of employees
400-500
Sector
Health Care
Industry Group
Pharmaceuticals, Biotechnology & Life Sciences
Industry
Biotechnology
Report inaccurate data
Request an update to help us keep the brand up-to-date.
